2018-05-072018-05-072013-03-081744-8301http://hdl.handle.net/2133/11302Metronomic chemotherapy (MCT), the chronic administration, at regular intervals, of low doses of chemotherapeutic drugs, without extended rest periods, allows chronic treatment with therapeutic efficacy and low toxicity. Our pre-clinical results suggested that combined MCT with cyclophosphamide (CY) and celecoxib (CEL) could inhibit breast cancer growth. The aim of this study was to determine the toxicity, safety and efficacy of the oral chronic administration of CY 50 mg p.o. daily, plus CEL 400 mg (200 mg p.o. bid) in advanced breast cancer patients (ABCP). The therapeutic response consisted in stable disease in a high proportion of patients and one partial response. The overall clinical benefit rate obtained was 66.7%. Toxicity was low. Evaluation of quality of life showed no changes during the response period. MCT with CY + Cel is safe and shows therapeutic effect in ABCP.application/pdf1-27engopenAccessBreast cancerBiomarkersMetronomic chemotherapyCyclophosphamideCelecoxibarticleAutoresFuture Medicine LtdFuture Medicine Ltd y sus licenciantes poseen los derechos de autor de todo el material contenido en este sitio. Ningún material puede revenderse o publicarse en otro lugar sin el consentimiento por escrito, salvo que lo autorice una licencia de Future Medicine Ltd o en la medida en que lo exija la ley aplicable.